Jardiance vs Farxiga: Combining the Two (Rationale + Risk)

What Are Jardiance and Farxiga, and How Do They Work?

Jardiance (empagliflozin, 10 mg or 25 mg once daily) and Farxiga (dapagliflozin, 10 mg once daily) block the SGLT2 transporter in the proximal tubule of the kidney, forcing roughly 60 to 90 grams of glucose into the urine each day [1]. That glucosuria lowers fasting plasma glucose, reduces HbA1c, and generates a mild osmotic diuresis that drops both systolic blood pressure and body weight without requiring insulin secretion.

The Shared Mechanism

Because both drugs act on the same transporter with similar receptor occupancy at therapeutic doses, adding the second agent to a full dose of the first does not double glucose excretion. The SGLT2 transporter becomes nearly saturated at the approved single-agent doses. A second inhibitor occupying the same target cannot meaningfully expand that effect [2].

Approved Indications Side by Side

Empagliflozin holds FDA approval for type 2 diabetes (2014), heart failure regardless of ejection fraction (2021 for HFrEF, 2022 for HFpEF), and CKD [3]. Dapagliflozin holds FDA approval for type 2 diabetes (2012), HFrEF (2020), HFpEF (2022), and CKD [4]. The overlapping indication list is one reason clinicians sometimes wonder whether using both could capture some additive benefit. It cannot, and the mechanism explains why.

EMPA-REG OUTCOME vs DAPA-HF: What the Key Trials Actually Showed

These two trials are frequently cited together as though their results are interchangeable. The numbers are close but not identical, and the populations differed enough to matter for individual patient decisions.

EMPA-REG OUTCOME (2015)

EMPA-REG OUTCOME enrolled 7,020 adults with type 2 diabetes and established cardiovascular disease [5]. Empagliflozin 10 mg or 25 mg versus placebo, on top of standard care, reduced the three-point MACE outcome (CV death, nonfatal MI, nonfatal stroke) by 14% (HR 0.86, 95% CI 0.74 to 0.99, P<0.001 for noninferiority; P=0.04 for superiority) [5]. The most striking finding was a 38% relative reduction in cardiovascular death (HR 0.62, 95% CI 0.49 to 0.77, P<0.001) [5]. Hospitalization for heart failure dropped 35% (HR 0.65, 95% CI 0.50 to 0.85, P<0.001) [5].

DAPA-HF (2019)

DAPA-HF enrolled 4,744 patients with heart failure with reduced ejection fraction (EF <40%), roughly 42% of whom did not have type 2 diabetes [6]. Dapagliflozin 10 mg versus placebo reduced the composite of worsening heart failure or cardiovascular death by 26% (HR 0.74, 95% CI 0.65 to 0.85, P<0.001) [6]. The benefit held whether or not participants had diabetes, a finding that shaped subsequent HF guidelines from both the ACC/AHA and the European Society of Cardiology.

What the Trials Do Not Tell Us About Combining Both Drugs

Neither EMPA-REG OUTCOME nor DAPA-HF included an arm that combined two SGLT2 inhibitors. No randomized controlled trial has ever tested empagliflozin plus dapagliflozin head-to-head or in combination against either drug alone. Any claim that combining them confers additional cardiovascular protection is extrapolation without supporting data [7].

The Rationale People Cite for Combining Both Agents

Patients and occasionally clinicians raise several arguments for stacking both drugs. Each argument has a specific flaw.

Argument 1: Different Molecules, Possibly Additive Effects

Empagliflozin and dapagliflozin differ in molecular structure, binding affinity, and pharmacokinetic profile. Empagliflozin has a slightly higher selectivity ratio for SGLT2 over SGLT1, and dapagliflozin has a longer half-life in some populations. These pharmacological differences do not translate into additive clinical outcomes when both drugs are given together because SGLT2 occupancy in the proximal tubule is already near-maximal with either agent at approved doses [2]. A second drug targeting the same saturated transporter adds toxicity, not efficacy.

Argument 2: One Drug for Diabetes, One for Heart Failure

Some clinicians reason that if a patient's cardiologist prescribed dapagliflozin for HFrEF and the endocrinologist separately prescribed empagliflozin for diabetes, the patient may be taking both without anyone flagging the duplication. This scenario reflects a care coordination gap, not a pharmacological rationale. The ADA Standards of Medical Care in Diabetes (2024) state that SGLT2 inhibitors with proven CV or renal benefit should be used as single-agent add-on therapy; no guideline recommends dual SGLT2 use [8].

Argument 3: Renal Protective Effects Are Additive

Both drugs slow CKD progression. DAPA-CKD (N=4,304) showed dapagliflozin reduced the composite of sustained eGFR decline ≥50%, end-stage kidney disease, or renal/CV death by 39% versus placebo (HR 0.61, 95% CI 0.51 to 0.72, P<0.001) [9]. EMPA-KIDNEY (N=6,609) showed empagliflozin reduced the primary kidney disease progression or CV death endpoint by 28% (HR 0.72, 95% CI 0.64 to 0.82, P<0.001) [10]. Again, these were single-agent trials. No trial has demonstrated that combining both agents produces greater renal protection than maximal dosing of one [7].

The table below summarizes the decision framework for choosing between the two drugs rather than combining them.

| Clinical Priority | Preferred Agent | Key Trial | |---|---|---| | CV mortality reduction in T2D + established ASCVD | Empagliflozin (Jardiance) | EMPA-REG OUTCOME [5] | | HFrEF in patients without T2D | Dapagliflozin (Farxiga) | DAPA-HF [6] | | CKD with albuminuria (eGFR 25 to 75) | Either; dapagliflozin has DAPA-CKD data | DAPA-CKD [9] | | HFpEF (EF ≥50%) | Either; both approved | EMPEROR-Preserved, DELIVER | | Formulary cost is primary driver | Whichever is covered | N/A |

The Real Risks of Taking Both Jardiance and Farxiga Simultaneously

Doubling up on SGLT2 inhibitors does not double efficacy, but the adverse-effect burden climbs measurably.

Genital Mycotic Infections

Both drugs increase vulvovaginal candidiasis and balanitis by creating a high-glucose urinary environment. In EMPA-REG OUTCOME, genital infections occurred in 6.4% of empagliflozin-treated women versus 1.8% on placebo [5]. Prescribing both agents would likely push that incidence higher, though no trial has quantified the exact combined rate. Patients with recurrent yeast infections on one SGLT2 inhibitor should not add a second; switching to a GLP-1 receptor agonist or a different drug class is the better option.

Volume Depletion and Hypotension

The osmotic diuresis from SGLT2 inhibition reduces plasma volume by roughly 7% within the first weeks of therapy [11]. Adding a second agent with the same mechanism could compound that effect, raising the risk of symptomatic hypotension and acute kidney injury, especially in elderly patients or those already taking loop diuretics. The FDA labeling for both drugs warns about volume depletion [3,4].

Diabetic Ketoacidosis (DKA)

SGLT2 inhibitors lower insulin requirements, suppress glucagon, and shift metabolism toward ketogenesis. DKA risk is estimated at roughly 0.1 to 0.2 per 100 patient-years with single-agent SGLT2 therapy in type 2 diabetes [12]. Combining two agents that promote ketogenesis could plausibly increase that risk, particularly during fasting, surgery, or acute illness. The FDA issued a Drug Safety Communication on SGLT2-associated DKA in 2015 [13].

Lower-Limb Amputation Signal

Canagliflozin's CANVAS trial (N=10,142) reported a doubling of lower-limb amputation risk, with 6.3 vs 3.4 participants per 1,000 patient-years [14]. This signal has not been replicated with empagliflozin or dapagliflozin at the same magnitude, but it raised awareness of a class-wide concern. Using two SGLT2 inhibitors in a patient with peripheral artery disease or prior foot ulcers adds theoretical risk with no offsetting benefit [14].

Fournier's Gangrene

The FDA added a black-box warning for necrotizing fasciitis of the perineum (Fournier's gangrene) to all SGLT2 inhibitor labels in 2018 after identifying 12 cases in postmarket surveillance [15]. Though rare, the severity of the condition and the absence of any efficacy rationale make dual SGLT2 use unjustifiable in a risk-benefit analysis.

Should You Switch from Jardiance to Farxiga (or Vice Versa)?

Switching is the correct move in several specific situations. The goal is to find the single best SGLT2 inhibitor for that patient's primary indication and comorbidities, then stay on it.

When Switching Makes Clinical Sense

A patient stable on empagliflozin for diabetes who develops HFrEF without diabetes might be switched to dapagliflozin if the cardiologist prefers the DAPA-HF trial population data, or if formulary coverage makes dapagliflozin less expensive. Conversely, a patient on dapagliflozin with established ASCVD and a primary goal of CV mortality reduction might be switched to empagliflozin given the more pronounced CV death reduction in EMPA-REG OUTCOME (38% relative risk reduction vs. A less differentiated signal for dapagliflozin in DECLARE-TIMI 58) [5,16].

How to Switch

There is no washout period required when transitioning between SGLT2 inhibitors because neither agent accumulates in tissue. Stop one on day one, start the other the same day or the following morning. Monitor blood pressure and renal function at two to four weeks post-switch, particularly in older adults or those with baseline eGFR <45 mL/min/1.73m² [3,4].

When Neither Agent Is the Right Choice

If a patient has recurrent genital infections on one SGLT2 inhibitor, switching to the other agent of the same class is unlikely to resolve the problem. GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound) offer cardiovascular and weight-reduction benefits without the mycotic infection mechanism. In STEP-1 (N=1,961), semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% on placebo [17], which itself improves glycemic control and reduces HF symptoms.

Jardiance vs Farxiga: Head-to-Head Glycemic and Weight Data

No large RCT has directly compared empagliflozin with dapagliflozin in a head-to-head design. Indirect comparisons drawn from their respective placebo-controlled trials show broadly similar glycemic efficacy.

HbA1c Reduction

Empagliflozin 10 mg reduces HbA1c by approximately 0.62 to 0.78% from baseline in monotherapy trials [1]. Dapagliflozin 10 mg reduces HbA1c by approximately 0.54 to 0.77% [2]. The ranges overlap completely. Neither drug holds a clinically meaningful advantage for glucose lowering alone.

Body Weight

Both drugs reduce body weight by 2 to 3 kg over 24 weeks in placebo-controlled trials, driven primarily by glucosuria-related caloric loss and the osmotic diuresis effect [1,2]. The weight reduction is modest compared with GLP-1 receptor agonists and should not be the primary reason for choosing either agent.

Blood Pressure

Systolic blood pressure falls by roughly 3 to 5 mmHg with either drug at standard doses, largely from the diuretic effect [1,2]. This is clinically useful in hypertensive patients with diabetes but does not differentiate the two agents from each other.

Drug Interactions, Renal Thresholds, and Special Populations

eGFR Thresholds

For glycemic benefit, both drugs require eGFR ≥45 mL/min/1.73m². Below that threshold, glucosuria diminishes and blood-sugar lowering becomes unreliable. For heart failure and CKD indications, both drugs retain benefit at eGFR as low as 20 to 25 mL/min/1.73m², which is why they are continued even in advanced CKD [3,4]. Combining both agents does not extend that eGFR floor.

Loop Diuretics

Adding either SGLT2 inhibitor to furosemide or torsemide amplifies diuresis. The EMPEROR-Reduced trial showed empagliflozin reduced loop diuretic dose requirements over time, suggesting the two drug classes have partially overlapping volume effects [18]. Combining empagliflozin and dapagliflozin in a patient already on a loop diuretic creates meaningful dehydration and electrolyte risk.

Insulin and Sulfonylureas

SGLT2 inhibitors lower blood glucose independently of insulin. When combined with insulin or a sulfonylurea, hypoglycemia risk rises. Using two SGLT2 inhibitors together in an insulin-dependent patient compounds the insulin dose reduction already required by a single SGLT2 inhibitor [8].

Pregnancy and Lactation

Both drugs are contraindicated in the second and third trimesters based on animal data showing renal dysgenesis and on the theoretical risk of neonatal glucose homeostasis disruption [3,4]. Neither drug has safety data in lactation. Dual SGLT2 use in a patient who becomes pregnant would require immediate discontinuation of both.

What Prescribers and Guidelines Say

The 2024 ADA Standards of Medical Care in Diabetes recommend selecting a single SGLT2 inhibitor with the specific cardiovascular, renal, or heart failure indication that matches the patient's dominant comorbidity [8]. The document does not mention or endorse dual SGLT2 therapy.

The 2022 ACC/AHA/HFSA Guideline for the Management of Heart Failure gives a Class I recommendation (Level of Evidence A) for SGLT2 inhibitor use in symptomatic HFrEF to reduce HF hospitalizations and CV death [19]. The guideline specifies a single SGLT2 inhibitor as the standard and makes no provision for combining two agents.

As the 2022 ACC/AHA/HFSA guideline states directly: "In patients with symptomatic chronic HFrEF, SGLT2i are recommended to reduce hospitalization for HF and cardiovascular death, regardless of the presence or absence of type 2 diabetes" [19]. The singular "SGLT2i" language is unambiguous.

Practical Prescribing Summary

Choosing between empagliflozin and dapagliflozin comes down to three variables: the patient's primary indication, their formulary, and tolerability history. Combining the two agents serves no validated clinical purpose and carries real additive harm.

Use empagliflozin (Jardiance 10 mg daily) when the primary goal is cardiovascular mortality reduction in a patient with type 2 diabetes and established ASCVD, based on EMPA-REG OUTCOME's 38% relative reduction in CV death [5].

Use dapagliflozin (Farxiga 10 mg daily) when the patient has HFrEF with or without diabetes and the DAPA-HF population most closely matches their profile, or when DAPA-CKD data is the most relevant renal evidence [6,9].

Switch rather than stack. If a patient changes indication or loses formulary coverage, transition directly from one agent to the other on the same day with no washout period. The ADA 2024 glycemic target for most non-pregnant adults remains HbA1c <7%, and a single well-chosen SGLT2 inhibitor reaches that target at least as well as any two-drug combination within the same class [8].